Related Experiment Video

Updated: Aug 15, 2026

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube (SWCNT)-delivered MALAT1 Antisense Oligos
07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube (SWCNT)-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

Regulation of NF-kB in multiple myeloma: therapeutic implications

Rena Feinman1, David S Siegel, James Berenson

  • 1Department of Surgery, UMDNJ-New Jersey Medical School, 185 South Orange Avenue MSB-G510, Newark, NJ 07103, USA. feinmarr@umdnj.edu

Clinical Advances in Hematology & Oncology : H&O
|September 17, 2005
PubMed

Insights

Nuclear factor kappa B (NF-kappaB) is crucial in cancer drug resistance, particularly in multiple myeloma. Understanding its complex regulation offers new therapeutic strategies for this cancer.

Area of Science:

  • Molecular Biology
  • Cancer Biology
  • Immunology

Background:

  • Nuclear factor kappa B (NF-kappaB) is a key transcription factor family involved in inflammation, immune responses, stress, oncogenesis, cell migration, and angiogenesis.
  • Aberrant NF-kappaB activation is linked to drug resistance in various cancers, including multiple myeloma.
  • NF-kappaB target gene expression is context-dependent, varying with cellular environment and inducer type.

Purpose of the Study:

  • To highlight the regulatory mechanisms underlying constitutive NF-kappaB activation.
  • To provide a rationale for developing targeted therapies against NF-kappaB in multiple myeloma.

Main Methods:

  • Review of regulatory mechanisms of NF-kappaB activity.
  • Analysis of NF-kappaB's role in multiple myeloma drug resistance.

Main Results:

  • NF-kappaB regulation involves multiple levels, including the IkappaB kinase (IKK) complex, IkappaB family members, transcription factor recruitment, and p65 post-translational modifications.
  • Constitutive NF-kappaB activation contributes to drug resistance in multiple myeloma.

Conclusions:

  • The intricate regulation of NF-kappaB presents multiple targets for therapeutic intervention.
  • Targeting NF-kappaB is a promising strategy for overcoming drug resistance in multiple myeloma.

More Related Videos

An Orthotopic Sciatic Nerve Xenograft for Neurofibromatosis Type 1 Neurofibromas03:53

An Orthotopic Sciatic Nerve Xenograft for Neurofibromatosis Type 1 Neurofibromas

Published on: October 10, 2025

Genetic Profiling and Genome-Scale Dropout Screening to Identify Therapeutic Targets in Mouse Models of Malignant Peripheral Nerve Sheath Tumor09:33

Genetic Profiling and Genome-Scale Dropout Screening to Identify Therapeutic Targets in Mouse Models of Malignant Peripheral Nerve Sheath Tumor

Published on: August 25, 2023

Related Concept Videos

NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...